Advertisement

Medication Use and Polypharmacy in Older Adults

  • Marty L. EngEmail author
  • James T. BirchJr.
Chapter

Abstract

Urinary system problems related to voiding are very common in older adults. Urinary incontinence is the most common complaint and most troublesome to manage in the older adult. Identifying the type of incontinence is the first step to approaching treatment or management. The symptom of urinary frequency is also problematic particularly when the older adult has limitations in mobility or cognitive deficits. These issues and concerns are often precipitated or exacerbated by common medications that are prescribed by physicians. The purpose of this chapter is to highlight the pharmacokinetic and pharmacodynamic changes that occur with aging, describe the impact of polypharmacy on bladder dysfunction, define the prescribing cascade and its impact on urinary symptoms, and identify the therapeutic classes of medications that can be the most problematic for bladder and voiding problems in the older adult.

Keywords

Urinary Incontinence Urinary Retention Stress Incontinence Urge Incontinence Urinary Frequency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Gallagher PF, O’Connor MN, O’Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther. 2011;89:845–54.PubMedCrossRefGoogle Scholar
  2. 2.
    Tamura BK, Bell CL, Lubimir K, Iwasaki WN, Ziegler LA, Masaki KH. Physician intervention for medication reduction in a nursing home: the polypharmacy outcomes project. J Am Med Dir Assoc. 2011;12:326–30.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Dwyer LL, Han B, Woodwell DA, Rechtsteiner EA. Polypharmacy in nursing home residents in the United States: results of the 2004 National Nursing Home Survey. Am J Geriatr Pharmacother. 2010;8:63–72.PubMedCrossRefGoogle Scholar
  4. 4.
    Loya AM, Gonzalez-Stuart A, Rivera JO. Prevalence of polypharmacy, polyherbacy, nutritional supplement use and potential product interactions among older adults living on the United States-Mexico border: a descriptive, questionnaire-based study. Drugs Aging. 2009;26:423–36.PubMedCrossRefGoogle Scholar
  5. 5.
    Heuberger RA, Caudell K. Polypharmacy and nutritional status in older adults: a cross-sectional study. Drugs Aging. 2011;28:315–23.PubMedCrossRefGoogle Scholar
  6. 6.
    Bourgeois FT, Shannon MW, Valim C, Mandl KD. Adverse drug events in the outpatient setting: an 11-year national analysis. Pharmacoepidemiol Drug Saf. 2010;19:901–10.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Aparasu RR, Mort JR, Brandt H. Polypharmacy trends in office visits by the elderly in the United States, 1990 and 2000. Res Social Adm Pharm. 2005;1:446–59.PubMedCrossRefGoogle Scholar
  8. 8.
    Nobili A, Licata G, Salerno F, et al. Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol. 2011;67:507–19.PubMedCrossRefGoogle Scholar
  9. 9.
    Nobili A, Franchi C, Pasina L, et al. Drug utilization and polypharmacy in an Italian elderly population: the EPIFARM-elderly project. Pharmacoepidemiol Drug Saf. 2011;20:488–96.PubMedCrossRefGoogle Scholar
  10. 10.
    Slabaugh SL, Maio V, Templin M, Abouzaid S. Prevalence and risk of polypharmacy among the elderly in an outpatient setting: a retrospective cohort study in the Emilia-Romagna region. Italy Drugs Aging. 2010;27:1019–28.Google Scholar
  11. 11.
    Harugeri A, Joseph J, Parthasarathi G, Ramesh M, Guido S. Prescribing patterns and predictors of high-level polypharmacy in the elderly population: a prospective surveillance study from two teaching hospitals in India. Am J Geriatr Pharmacother. 2010;8:271–80.PubMedCrossRefGoogle Scholar
  12. 12.
    Gokce Kutsal Y, Barak A, Atalay A, et al. Polypharmacy in the elderly: a multicenter study. J Am Med Dir Assoc. 2009;10:486–90.PubMedCrossRefGoogle Scholar
  13. 13.
    Wawruch M, Zikavska M, Wsolova L, et al. Polypharmacy in elderly hospitalised patients in Slovakia. Pharm World Sci. 2008;30:235–42.PubMedCrossRefGoogle Scholar
  14. 14.
    Schuler J, Duckelmann C, Beindl W, Prinz E, Michalski T, Pichler M. Polypharmacy and inappropriate prescribing in elderly internal-medicine patients in Austria. Wien Klin Wochenschr. 2008;120:733–41.PubMedCrossRefGoogle Scholar
  15. 15.
    Rozenfeld S, Fonseca MJ, Acurcio FA. Drug utilization and polypharmacy among the elderly: a survey in Rio de Janeiro City, Brazil Rev Panam Salud Publica. 2008;23:34–43.PubMedCrossRefGoogle Scholar
  16. 16.
    Haider SI, Johnell K, Thorslund M, Fastbom J. Analysis of the association between polypharmacy and socioeconomic position among elderly aged > or =77 years in Sweden. Clin Ther. 2008;30:419–27.PubMedCrossRefGoogle Scholar
  17. 17.
    Corsonello A, Pedone C, Corica F, Incalzi RA. Polypharmacy in elderly patients at discharge from the acute care hospital. Ther Clin Risk Manag. 2007;3:197–203.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Linjakumpu T, Hartikainen S, Klaukka T, Veijola J, Kivela SL, Isoaho R. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol. 2002;55:809–17.PubMedCrossRefGoogle Scholar
  19. 19.
    Jyrkka J, Enlund H, Lavikainen P, Sulkava R, Hartikainen S. Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf. 2011;20:514–22.PubMedCrossRefGoogle Scholar
  20. 20.
    Banerjee A, Mbamalu D, Ebrahimi S, Khan AA, Chan TF. The prevalence of polypharmacy in elderly attenders to an emergency department - a problem with a need for an effective solution. Int J Emerg Med. 2011;4:22.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Alic A, Pranjic N, Ramic E. Polypharmacy and decreased cognitive abilities in elderly patients. Med Arh. 2011;65:102–5.PubMedGoogle Scholar
  22. 22.
    Jyrkka J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Patterns of drug use and factors associated with polypharmacy and excessive polypharmacy in elderly persons: results of the Kuopio 75+ study: a cross-sectional analysis. Drugs Aging. 2009;26:493–503.PubMedCrossRefGoogle Scholar
  23. 23.
    Jyrkka J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging. 2009;26:1039–48.PubMedCrossRefGoogle Scholar
  24. 24.
    Lassila HC, Stoehr GP, Ganguli M, et al. Use of prescription medications in an elderly rural population: the MoVIES project. Ann Pharmacother. 1996;30:589–95.PubMedGoogle Scholar
  25. 25.
    Fillit HM, Futterman R, Orland BI, et al. Polypharmacy management in Medicare managed care: changes in prescribing by primary care physicians resulting from a program promoting medication reviews. Am J Manag Care. 1999;5:587–94.PubMedGoogle Scholar
  26. 26.
    Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287:337–44.PubMedCrossRefGoogle Scholar
  27. 27.
    Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5:345–51.PubMedCrossRefGoogle Scholar
  28. 28.
    Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (Screening Tool of Older Persons’ Prescriptions) and START (Screening Tool to Alert Doctors to Right Treatment): Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83.Google Scholar
  29. 29.
    Viktil KK, Blix HS, Moger TA, Reikvam A. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 2007;63:187–95.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Tobi H, Faber A, van den Berg PB, et al. Studying co-medication patterns: The impact of definitions. Pharmacoepidemiol Drug Saf. 2007;16(4):405–11.Google Scholar
  31. 31.
    Lau DT, Mercaldo ND, Harris AT, Trittschuh E, Shega J, Weintraub S. Polypharmacy and potentially inappropriate medication use among community-dwelling elders with dementia. Alzheimer Dis Assoc Disord. 2010;24:56–63.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Buck MD, Atreja A, Brunker CP, et al. Potentially inappropriate medication prescribing in outpatient practices: prevalence and patient characteristics based on electronic health records. Am J Geriatr Pharmacother. 2009;7:84–92.PubMedCrossRefGoogle Scholar
  33. 33.
    Huang ES, Karter AJ, Danielson KK, Warton EM, Ahmed AT. The association between the number of prescription medications and incident falls in a multi-ethnic population of adult type-2 diabetes patients: The Diabetes and Aging Study. J Gen Intern Med. 2009;25(2):141–6.Google Scholar
  34. 34.
    Lau DT, Mercaldo ND, Shega JW, Rademaker A, Weintraub S. Functional decline associated with polypharmacy and potentially inappropriate medications in community-dwelling older adults with dementia. Am J Alzheimers Dis Other Demen. 2011;26(8):606–15.Google Scholar
  35. 35.
    American Geriatric Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60:616–31.CrossRefGoogle Scholar
  36. 36.
    Hamilton H, Gallagher P, Ryan C, Byrne S, O’Mahony D. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med. 2011;171(11):1013–19.Google Scholar
  37. 37.
    Trygstad TK, Christensen DB, Wegner SE, Sullivan R, Garmise JM. Analysis of the North Carolina long-term polypharmacy initiative: a multiple-cohort approach using propensity-score matching for both evaluation and targeting. Clin Ther. 2009;31(9):2018–37.Google Scholar
  38. 38.
    Flood KL, Carroll MB, Le CV, Brown CJ. Polypharmacy in hospitalized older adult cancer patients: experience from a prospective, observational study of an oncology acute care for elderly unit. Am J Geriatr Pharacother. 2009;7(3):151–8.Google Scholar
  39. 39.
    Weber V, White A, McIlvired R. An electronic medical record-based intervention to reduce polypharmacy and falls in an ambulatory rural elderly population. J Gen Intern Med. 2008;23(4):399–404.Google Scholar
  40. 40.
    Garfinkel D, Zur-Gil S, Ben-Israel J. The war against polypharmacy: a new cost-effective geriatric palliative approach for improving drug therapy in disabled elderly people. Isr Med Assoc J. 2007;9(6):430–4.Google Scholar
  41. 41.
    Samsa GP, Hanlon JT, Schmader K, et al. A summated score for the Medication Appropriateness Index: Development and assessment of clinimetric properties including content validity. J Clin Epidemiol. 1994;47(8):891–6.Google Scholar
  42. 42.
    Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46:1481–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67–76.PubMedCrossRefGoogle Scholar
  44. 44.
    Dharmarajan TS, Ugalino JA. Understanding the pharmacology of aging. Hosp Physician. 2000;1(1):1–12.Google Scholar
  45. 45.
    Kaeslti LZ, Wasilewski-Rasca AF, Bonnabry P, Vogt-Ferrier N. Use of transdermal drug formulations in the elderly. Drugs Aging. 2008;35(4):269–80.Google Scholar
  46. 46.
    Cockcroft DW, Gault MH. Prediction of creatinine clearance form serum creatinine. Nephron. 1976;16:31–41.PubMedCrossRefGoogle Scholar
  47. 47.
    Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the Modification of Diet in Renal Disease Study Equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–54.Google Scholar
  48. 48.
    Hanlon JT, Aspinall SL, Semla TP, et al. Consensus guidelines for oral dosing of primarily renally cleared medications in older adults. J Am Geriatr Soc. 2009;57(2):335–40.PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005;165(7):808–13.PubMedCrossRefGoogle Scholar
  50. 50.
    Boudreau DM, Yu O, Gray SL, Raebel MA, Johnson J, Larson EB. Concomitant use of cholinesterase inhibitors and anticholinergics: Prevalence and outcomes. J Am Geriatr Soc. 2011;59:2069–76.Google Scholar
  51. 51.
    Darrah DM, Griebling TL, Silverstein JH. Postoperative urinary retention. Anesthesiol Clin. 2009;27:465–84.PubMedCrossRefGoogle Scholar
  52. 52.
    Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168:508–13.PubMedCrossRefGoogle Scholar
  53. 53.
    Wagg A, Verdejo C, Molander U. Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder. Int J Clin Pract. 2010;64:1279–86.PubMedCrossRefGoogle Scholar
  54. 54.
    Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225–33.PubMedCentralPubMedGoogle Scholar
  55. 55.
    Carriere I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med. 2009;169:1317–24.PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Campbell NL, Boustani MA, Lane KA, et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology. 2010;75:152–9.PubMedCentralPubMedCrossRefGoogle Scholar
  57. 57.
    Campbell N, Perkins A, Hui S, Khan B, Boustani M. Association between prescribing of anticholinergic medications and incident delirium: a cohort study. J Am Geriatr Soc. 2011;59(Suppl 2):S277–81.Google Scholar
  58. 58.
    Fox C, Livingston G, Maidment ID, et al. The impact of anticholinergic burden in Alzheimer’s dementia-the LASER-AD study. Age Ageing. 2011;40:730–5.PubMedCrossRefGoogle Scholar
  59. 59.
    Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc. 2008;56:1333–41.PubMedCrossRefGoogle Scholar
  60. 60.
    Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315(7115):1096–9.PubMedCentralPubMedCrossRefGoogle Scholar
  61. 61.
    Shah D, Badlani G. Treatment of overactive bladder and incontinence in the elderly. Rev Urol. 2002;4(Suppl 4):S38–43.PubMedCentralPubMedGoogle Scholar
  62. 62.
    Srulevich M, Chopra A. Voiding disorders in long-term are. Ann Long Term Care Clin Care Aging. 2008;16(12 Supplement):39–43.Google Scholar
  63. 63.
    Resnick NM, Yalla SV. Management of urinary incontinence in the elderly. N Engl J Med. 1985;313(13):800–5.PubMedCrossRefGoogle Scholar
  64. 64.
    Drake MJ, Nixon PM, Crew JP. Drug-induced bladder and urinary disorders. Incidence, prevention and management. Drug Saf. 1998;19(1):45–55.PubMedCrossRefGoogle Scholar
  65. 65.
    Weiss BD. Diagnostic evaluation of urinary incontinence in geriatric patients. Am Fam Physician. 1998;57(11):2675–84, 88, 90.Google Scholar
  66. 66.
    Hendrix SL, Cochrane BB, Nygaard IE, et al. Effects of estrogen with and without progestin in urinary incontinence. JAMA. 2005;293(8):935–48.Google Scholar
  67. 67.
    Ekundayo OJ, Markland A, Lefante C, et al. Association of diuretic use and overactive bladder syndrome in older adults: a propensity score analysis. Arch Gerontol Geriatr. 2009;49(1):64–8.PubMedCentralPubMedCrossRefGoogle Scholar
  68. 68.
    Jura YH, Townsend MK, Curhan GC, Resnick NM, Grodstein F. Caffeine intake, and the risk of stress, urgency and mixed urinary incontinence. J Urol. 2011;185(5):1775–80.PubMedCentralPubMedGoogle Scholar
  69. 69.
    Townsend MK, Resnick NM, Grodstein F. Caffeine intake and risk of urinary incontinence progression among women. Obstet Gynecol. 2012;119(5):950–7.PubMedCentralPubMedCrossRefGoogle Scholar
  70. 70.
    Seaman AM. Caffeine not tied to worsening urinary incontinence. 2012. http://www.nlm.nih.gov/medlineplus/news/fullstory_124610.html. Accessed 27 Apr 2012.
  71. 71.
    Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R. Drug-induced urinary retention: incidence, management and prevention. Drug Saf. 2008;31(5):373–88.PubMedCrossRefGoogle Scholar
  72. 72.
    Dolin SJ, Cashman JN. Tolerability of acute postoperative pain management: nausea, vomiting, sedation, pruritus, and urinary retention. Evidence from published data. Br J Anaesth. 2005;95(5):584–91.PubMedGoogle Scholar
  73. 73.
    Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. J Am Geriatr Soc. 2007;55:S373–82.PubMedCrossRefGoogle Scholar
  74. 74.
    Wenger NS, Roth CP, Shekelle P. Introduction to the assessing care of vulnerable elders-3 quality indicator measurement set. J Am Geriatr Soc. 2007;55(Suppl 2):S247–252.PubMedCrossRefGoogle Scholar
  75. 75.
    Arora VM, McGory ML, Fung CH. Quality indicators for hospitalization and surgery in vulnerable elders. J Am Geriatr Soc. 2007;55:S347–58.PubMedCrossRefGoogle Scholar
  76. 76.
    Resnick B, Pacala JT. 2012 Beers Criteria. J Am Geriatr Soc. 2012;60(4):612–3.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Pharmacy PracticeSchool of Pharmacy, Cedarville UniversityCedarvilleUSA
  2. 2.Department of Family MedicineUniversity of Kansas HospitalKansas CityUSA

Personalised recommendations